TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a ...

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable ...

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher ...

Key limitations included nonstandardized diagnostic criteria, proxy-derived activity/symptom measures, recall bias for ...

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers ...

Projectiles such as grass, dirt, and rocks caused 77% of injuries, and eye protection, including eyeglasses, was documented ...

The FDA has approved olanzapine extended-release injectable suspension (Weltruza; Teva Pharmaceuticals), a once-monthly ...

For patients with a blood cancer, the choice of a chimeric antigen receptor (CAR) T-cell therapy or a bispecific antibody is rarely a simple one, explains Kerry Rogers, MD, associate professor at The ...

Kansteiner F. PhRMA launches new legal challenge as CMS brings 'most favored nation' pricing to Medicare Part B. Fierce ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content ...

Cost was cited at the top barrier to prescribing nonsteroidal mineralocorticoid antagonists (57%), sodium-glucose cotransporter 2 inhibitors (74%), and glucagon-like peptide 1 receptor agonists (84%).